CIPLADOC - Cipla Therapeutic Index

Therapeutic Index

Antiretrovirals

Back

Lamivir-S

Lamivudine and stavudine tablets

COMPOSITION

LAMIVIR-S – 30
Each tablet contains
Stavudine 30 mg
Lamivudine 150 mg

INDICATIONS

LAMIVIR-S tablets are indicated for the treatment of HIV infection as a component of combination antiretroviral therapy.

DOSAGE AND ADMINISTRATION

The interval between doses of Lamivir S should be 12 hours. Lamivir S may be taken with or without food.

Adults
LAMIVIR-S – 30
1 tablet twice daily for patients weighing <60 kg

Dose adjustment: Because it is a fixed-dose combination, LAMIVIR-S should not be prescribed for patients requiring dosage adjustment, such as those with reduced renal function (creatinine clearance ≤ 50 ml/min), or those experiencing dose-limiting adverse events.

CONTRAINDICATIONS

LAMIVIR-S is contraindicated in patients with clinically significant hypersensitivity (anaphylaxis) to any of the components contained in the formulation.

PACKAGING INFORMATION

LAMIVIR-S – 30 .........................Container of 60 tablets

For full prescribing information, click here

Last Updated: May 2009

Back